Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Eli Lilly and Company (LLY) Stock: Dips After New Psoriasis-Obesity Trial Data
Eli Lilly’s stock saw a 1.65% decline to $1,018.92 following the announcement of positive Phase 3b TOGETHER-PsO trial results. The trial demonstrated that a combination of Taltz and Zepbound significantly improved skin clearance and weight loss in patients with psoriasis and obesity compared to Taltz alone. Despite the clinical success, which offers a comprehensive treatment for these comorbid conditions, the market reacted with a short-term dip in the company’s share price.